Apollo Deal History & Licensing Activity
Apollo is a life sciences headquartered in US. Over the past three years, Apollo has been involved in 1 licensing and acquisition transaction, with a primary focus on Other (2 deals). The company currently has 10 active clinical trials, primarily in Women's Health.
Deals (12mo)
1
Active Trials
10
Top Modality
Other
Focus Area
Women's Health
Apollo Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Apollo in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Long-acting reversible contraceptives (LARC) business | Bayer | Other | Approved | other | Jul 10, 2026 |
Apollo Pipeline Focus
Therapeutic areas and modalities where Apollo is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Apollo Clinical Pipeline
Apollo has 10 active clinical trials across 6 development phases.
2
Not Applicable
1
Phase 4
1
Unknown
3
Phase 1
2
Phase 2
1
Phase 3
See How Your Asset Matches Apollo's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Women's Health assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Apollo Licensing & Deal Activity
Apollo is a life sciences company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Apollo ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Apollo include Women's Health (2 deals and trials), Cardiovascular (2 deals and trials), Autoimmune (1 deal and trial), and Infectious (1 deal and trial). In terms of modality, Apollo has shown particular interest in other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Apollo and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Apollo's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.